Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal
immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the
peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has
proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).